The latest announcement is out from Luye Pharma Group ( (HK:2186) ).
Luye Pharma Group Ltd. reported its annual financial results for the year ended December 31, 2024, highlighting a slight decrease in revenue by 1.3% to RMB6,061.4 million. Despite this, the company saw a 5.5% increase in EBITDA to RMB2,191.7 million and a 19.9% rise in profit before tax to RMB839.2 million. Net profit also increased by RMB105.9 million to RMB645.0 million. However, profit attributable to shareholders decreased by RMB60.7 million, and no dividend was proposed for the year. These results indicate a mixed financial performance, with improvements in certain profitability metrics but challenges in revenue growth and shareholder returns.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company incorporated in Bermuda, focusing on the development, production, and sale of innovative medications. The company operates in the healthcare industry, providing a range of pharmaceutical products aimed at improving patient outcomes.
YTD Price Performance: -5.56%
Average Trading Volume: 100
Technical Sentiment Signal: Buy
Current Market Cap: $1.18B
For an in-depth examination of 2186 stock, go to TipRanks’ Stock Analysis page.